Jubilant Ingrevia Limited has posted a strong finish to FY26, reporting its highest quarterly revenue in 14 quarters, driven by broad-based growth across Specialty Chemicals, Nutrition, and Chemical Intermediates, alongside improving margins and steady execution across key projects. 

For Q4 FY26, total revenue rose 12% year-on-year to Rs. 1,179 crore, while EBITDA increased 11% to Rs. 172 crore. Profit after tax (PAT) jumped 17% YoY to Rs. 86 crore, reflecting improved operating leverage and stronger product mix. On a sequential basis, performance accelerated sharply, with EBITDA up 26% and PAT surging 84% quarter-on-quarter. 

The company highlighted continued demand strength and pricing resilience despite global disruptions.  

“We are pleased to report a healthy performance in Q4 and FY26. Our Revenue grew 12% YoY and EBITDA increased 11% YoY in Q4 FY26, reflecting our strong execution. A key highlight for the quarter was our effective handling of the Middle East crisis, with no force majeure and zero production loss.  

"The other highlights include successful dispatch from our newly constructed Agro CDMO facility and the acquisition of Remidex to accelerate the growth of our Human Nutrition business.” 

Management also underscored a strengthening demand environment across chemicals and downstream sectors, supported by firming input costs and effective price pass-through. 

"Overall chemical Industry’s demand remains resilient despite Middle East disruptions. Volumes continue to grow, while pricing has firmed up in last few weeks due to higher crude-linked costs, with effective pass-through to customers. Pharmaceuticals continue to anchor growth with strong volumes and consistent demand.  

"Agrochem saw strong growth, with robust export visibility and successful price increases, especially in second half of the quarter. Nutrition and Personal Care markets witnessed volume and price-led growth, driven by Niacinamide, with strong demand in Feed and Cosmetics.” 

The Specialty Chemicals segment remained a key growth engine, with revenue rising to Rs. 516 crore, up 6% YoY and 13% QoQ. EBITDA margins strengthened to ~27%, reflecting improved realizations and volume recovery. 

“During the quarter, Specialty Chemicals showed strong momentum, driven by volume recovery despite stable pricing, with margins rising above 27%, reflecting robust fundamentals and resilience,” the company said. 

Growth was led by Pyridine and derivatives, along with steady expansion in Fine Chemicals and Diketene derivatives. The CDMO business also gained traction with higher realizations and commencement of a large agro contract. 

Nutrition & Health Solutions delivered a strong rebound, with revenue rising 21% YoY to Rs. 230 crore and EBITDA margins improving to 14%. 

“Growth was led by Niacinamide, supported by Cosmetics demand; Choline also improved with a surge in exports to Europe,” the company noted. 

The segment also saw strategic expansion through the acquisition of Remidex Pharma, strengthening its human nutrition and premix portfolio. 

Revenue from Chemical Intermediates rose 15% YoY to Rs. 433 crore, supported by stronger agrochemical and paracetamol demand and improved domestic volumes. 

Management highlighted that rising acetic acid prices and global supply disruptions are setting up a more favorable pricing environment ahead. 

Net debt-to-EBITDA improved to 0.99x, with net debt declining 11% in FY26, underscoring stronger cash generation and disciplined capital allocation. 

The Board recommended a final dividend of Rs. 2.50 per share (250%), taking the total FY26 dividend to Rs. 5 per share (500%). 

CEO and MD Deepak Jain said the company has strengthened resilience through the year despite external shocks. 

“Over the past year, we have made strong progress across all strategic pillars, building long-term growth while managing global challenges effectively. Despite Middle East disruptions impacting supply and prices, our diversified sourcing and agility ensured minimal disruption with effective cost pass-through.  

"Strong customer engagement and timely renegotiations have strengthened resilience, reflected in improved performance in Q4.” 

Looking ahead, the company signalled confidence in sustained momentum, with growth expected to be led by Specialty Chemicals and Nutrition, alongside recovery in Acetyls. 

“Early outcomes of our Pinnacle journey are clearly visible in our performance, with strong EBITDA growth, an improving portfolio mix, enhanced customer relationships, a robust opportunity pipeline, more efficient cost structure and balance sheet,” the management said. 

The company expects sequential growth in both revenue and EBITDA starting Q1 FY27, supported by capacity additions and ongoing investments such as the Gajraula Multi Purpose Plant (MPP), which is progressing as part of its CDMO expansion roadmap.